Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Lupin launches generic...

    Lupin launches generic Tetrabenazine Tablets

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-11-22T16:26:42+05:30  |  Updated On 16 Aug 2021 5:08 PM IST




    Mumbai: Pharma major Lupin announced the launch of Tetrabenazine Tablets, 12.5 mg and 25 mg having received an approval from the United States Food and Drug Administration (FDA) earlier.

    Lupin's Tetrabenazine Tablets, 12.5 mg and 25 mg are the generic equivalent of Valeant Pharmaceuticals North America, LLC's Xenazine® tablets. It is indicated for the treatment of chorea associated with Huntington's disease.

    Xenazine® tablets had annual sales of $153 million in the US (IQVIA MAT September 2018). Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorders

    Lupin is the 13th largest generics pharmaceutical company in terms of market capitalization and the 8th largest generics pharmaceutical company in terms of revenues globally. The Company is the 3rd largest pharmaceutical player in the US by prescriptions for the Total Market; 3
    rd
    largest Indian pharmaceutical company by global revenues ; 6th largest generic pharmaceutical player in Japan and 5th largest company in the Indian Pharmaceutical Market ).

    Also Read: Lupin gets USFDA nod to market Tetrabenazine tablets






    BSEchoreadrug makergenericHuntington’s diseaseIQVIALLCLupinneurological disordersTabletsTetrabenazinetreatmentUSFDAValeant PharmaceuticalsXenazine

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok